Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inspire Medical Systems (INSP) EBITDA (2017 - 2025)

Historic EBITDA for Inspire Medical Systems (INSP) over the last 9 years, with Q4 2025 value amounting to $135.9 million.

  • Inspire Medical Systems' EBITDA rose 29904.58% to $135.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $145.4 million, marking a year-over-year increase of 17298.34%. This contributed to the annual value of $145.4 million for FY2025, which is 17298.34% up from last year.
  • Latest data reveals that Inspire Medical Systems reported EBITDA of $135.9 million as of Q4 2025, which was up 29904.58% from $10.2 million recorded in Q3 2025.
  • In the past 5 years, Inspire Medical Systems' EBITDA ranged from a high of $135.9 million in Q4 2025 and a low of -$17.0 million during Q3 2022
  • For the 5-year period, Inspire Medical Systems' EBITDA averaged around $4.6 million, with its median value being -$6.0 million (2023).
  • Per our database at Business Quant, Inspire Medical Systems' EBITDA surged by 35284.51% in 2023 and then tumbled by 13582.79% in 2025.
  • Quarter analysis of 5 years shows Inspire Medical Systems' EBITDA stood at -$2.4 million in 2021, then soared by 240.62% to $3.4 million in 2022, then surged by 352.85% to $15.5 million in 2023, then skyrocketed by 119.47% to $34.1 million in 2024, then soared by 299.05% to $135.9 million in 2025.
  • Its EBITDA was $135.9 million in Q4 2025, compared to $10.2 million in Q3 2025 and -$3.4 million in Q2 2025.